<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.2.3" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>Health hot news</title>
	<link>http://www.globalepolicy.org</link>
	<description></description>
	<pubDate>Wed, 20 Aug 2008 08:00:00 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2.3</generator>
	<language>en</language>
			<item>
		<title>Manchester Royal Infirmary Performs The World&#8217;s 1000th Endovascular Aorto-Iliac Aneurysm Repair Using The Zenith(R) Branch Iliac Endovascular Graft</title>
		<link>http://www.globalepolicy.org/manchester-royal-infirmary-performs-the-worlds-1000th-endovascular-aorto-iliac-aneurysm-repair-using-the-zenithr-branch-iliac-endovascular-graft.htm</link>
		<comments>http://www.globalepolicy.org/manchester-royal-infirmary-performs-the-worlds-1000th-endovascular-aorto-iliac-aneurysm-repair-using-the-zenithr-branch-iliac-endovascular-graft.htm#comments</comments>
		<pubDate>Wed, 20 Aug 2008 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Cardiovascular / Cardiology]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://de29abedbdaa4bc9f32ab20fc721e46f</guid>
		<description><![CDATA[ In a major landmark for advanced interventional technology to treat aortic disease, the Zenith® Branch Iliac Endovascular Graft has been used to treat the world's 1,000th patient undergoing endovascular treatment for an aorto-iliac or iliac aneurysm. Mr Ferdinand Serracino-Inglott, one of only 200 vascular surgeons performing this type of surgery in Europe, carried out the minimally invasive endovascular procedure at Manchester Royal Infirmary.]]></description>
			<content:encoded><![CDATA[ In a major landmark for advanced interventional technology to treat aortic disease, the Zenith® Branch Iliac Endovascular Graft has been used to treat the world's 1,000th patient undergoing endovascular treatment for an aorto-iliac or iliac aneurysm. Mr Ferdinand Serracino-Inglott, one of only 200 vascular surgeons performing this type of surgery in Europe, carried out the minimally invasive endovascular procedure at Manchester Royal Infirmary.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/manchester-royal-infirmary-performs-the-worlds-1000th-endovascular-aorto-iliac-aneurysm-repair-using-the-zenithr-branch-iliac-endovascular-graft.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Total And Free PSA (PSA/fPSA) Assays Now Available For The Olympus AU3000i Immunoassay Analyser</title>
		<link>http://www.globalepolicy.org/total-and-free-psa-psafpsa-assays-now-available-for-the-olympus-au3000i-immunoassay-analyser.htm</link>
		<comments>http://www.globalepolicy.org/total-and-free-psa-psafpsa-assays-now-available-for-the-olympus-au3000i-immunoassay-analyser.htm#comments</comments>
		<pubDate>Wed, 20 Aug 2008 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Prostate / Prostate Cancer]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://1894ed618e44e0c9b00fd928f0fe2eb2</guid>
		<description><![CDATA[Olympus is pleased to announce the launch of highly sensitive and precise PSA (Prostate Specific Antigen) and fPSA assays for the Olympus AU3000i immunoassay analyser.  The use of PSA and fPSA is well established in the screening and management of prostate cancer. Olympus is joining this market with an extremely sensitive PSA assay with a functional sensitivity of 0.015 Âµg/L.]]></description>
			<content:encoded><![CDATA[Olympus is pleased to announce the launch of highly sensitive and precise PSA (Prostate Specific Antigen) and fPSA assays for the Olympus AU3000i immunoassay analyser.  The use of PSA and fPSA is well established in the screening and management of prostate cancer. Olympus is joining this market with an extremely sensitive PSA assay with a functional sensitivity of 0.015 Âµg/L.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/total-and-free-psa-psafpsa-assays-now-available-for-the-olympus-au3000i-immunoassay-analyser.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Starion Instrument&#8217;s Tissue Ligating Shears Ideal Solution For Endoscopic Radial Artery And Saphenous Vein Harvesting</title>
		<link>http://www.globalepolicy.org/starion-instruments-tissue-ligating-shears-ideal-solution-for-endoscopic-radial-artery-and-saphenous-vein-harvesting.htm</link>
		<comments>http://www.globalepolicy.org/starion-instruments-tissue-ligating-shears-ideal-solution-for-endoscopic-radial-artery-and-saphenous-vein-harvesting.htm#comments</comments>
		<pubDate>Wed, 20 Aug 2008 08:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Medical Devices / Diagnostics]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://59066cb10abf8ea3af93c41bddb5d7a8</guid>
		<description><![CDATA[Starion Instruments, a leading     surgical device company, today announced that a study presented at     the 2008 Annual Scientific Meeting of the International Society for     Minimally Invasive Cardiothoracic Surgery (ISMICS) found Starion's     Tissue Ligating Shears provides a safe and effective solution for     endoscopic harvesting of the radial artery and saphenous vein.]]></description>
			<content:encoded><![CDATA[Starion Instruments, a leading     surgical device company, today announced that a study presented at     the 2008 Annual Scientific Meeting of the International Society for     Minimally Invasive Cardiothoracic Surgery (ISMICS) found Starion's     Tissue Ligating Shears provides a safe and effective solution for     endoscopic harvesting of the radial artery and saphenous vein.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/starion-instruments-tissue-ligating-shears-ideal-solution-for-endoscopic-radial-artery-and-saphenous-vein-harvesting.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Clinical Studies Completed For HeartVue&#8217;s 6S Heart Screening System</title>
		<link>http://www.globalepolicy.org/clinical-studies-completed-for-heartvues-6s-heart-screening-system.htm</link>
		<comments>http://www.globalepolicy.org/clinical-studies-completed-for-heartvues-6s-heart-screening-system.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 20:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Cardiovascular / Cardiology]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://c37ad62b89ac6658d520572f0b002ab1</guid>
		<description><![CDATA[ Pegasus/Heartview LLC (PINKSHEETS: PGUZ) announced that they have now completed the required clinical studies, which are an integral part of the process required for the marketing of the Company's breakthrough HeartVue 6S Heart Screening System in North America.]]></description>
			<content:encoded><![CDATA[ Pegasus/Heartview LLC (PINKSHEETS: PGUZ) announced that they have now completed the required clinical studies, which are an integral part of the process required for the marketing of the Company's breakthrough HeartVue 6S Heart Screening System in North America.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/clinical-studies-completed-for-heartvues-6s-heart-screening-system.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Funding For Clinical Trials For New Probe To Detect Skin Cancer</title>
		<link>http://www.globalepolicy.org/funding-for-clinical-trials-for-new-probe-to-detect-skin-cancer.htm</link>
		<comments>http://www.globalepolicy.org/funding-for-clinical-trials-for-new-probe-to-detect-skin-cancer.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 10:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Dermatology]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://5cd366f398fea889a7386536f9653218</guid>
		<description><![CDATA[Assistant Professor James Tunnell has been awarded a Phase II Early Career Award from the Wallace H. Coulter Foundation to continue the development and testing of a device that uses light to detect skin cancer without the need for an invasive biopsy procedure.    The $260,000 grant will support Tunnell's work for the next two years to refine the device called a "clinical spectrometer" and to conduct additional clinical trials.]]></description>
			<content:encoded><![CDATA[Assistant Professor James Tunnell has been awarded a Phase II Early Career Award from the Wallace H. Coulter Foundation to continue the development and testing of a device that uses light to detect skin cancer without the need for an invasive biopsy procedure.    The $260,000 grant will support Tunnell's work for the next two years to refine the device called a "clinical spectrometer" and to conduct additional clinical trials.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/funding-for-clinical-trials-for-new-probe-to-detect-skin-cancer.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Olympic Medical Research Using GE Healthcare Technology Finds Enlarged Hearts Can Be Good Hearts</title>
		<link>http://www.globalepolicy.org/olympic-medical-research-using-ge-healthcare-technology-finds-enlarged-hearts-can-be-good-hearts.htm</link>
		<comments>http://www.globalepolicy.org/olympic-medical-research-using-ge-healthcare-technology-finds-enlarged-hearts-can-be-good-hearts.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 09:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Cardiovascular / Cardiology]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://70389d1f42ca8bef8abb07c51d64258c</guid>
		<description><![CDATA[GE Healthcare along with Olympic medical leaders announced at the Beijing 2008 Olympic Games, initial findings that recognize risks for sudden cardiac death and musculoskeletal injuries before they happen. The findings come from two Olympic athlete research studies conducted since the Torino 2006 Olympic Winter Games aimed at demonstrating that health monitoring and early intervention may lead to injury prevention and enhanced health.]]></description>
			<content:encoded><![CDATA[GE Healthcare along with Olympic medical leaders announced at the Beijing 2008 Olympic Games, initial findings that recognize risks for sudden cardiac death and musculoskeletal injuries before they happen. The findings come from two Olympic athlete research studies conducted since the Torino 2006 Olympic Winter Games aimed at demonstrating that health monitoring and early intervention may lead to injury prevention and enhanced health.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/olympic-medical-research-using-ge-healthcare-technology-finds-enlarged-hearts-can-be-good-hearts.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Asuragen, Inc. Launches Signature® NPM1 Mutations (RUO): A Rapid Multiplex Assay For The Detection Of NPM1 Mutations</title>
		<link>http://www.globalepolicy.org/asuragen-inc-launches-signature%c2%ae-npm1-mutations-ruo-a-rapid-multiplex-assay-for-the-detection-of-npm1-mutations.htm</link>
		<comments>http://www.globalepolicy.org/asuragen-inc-launches-signature%c2%ae-npm1-mutations-ruo-a-rapid-multiplex-assay-for-the-detection-of-npm1-mutations.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 09:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Lymphoma / Leukemia]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://015d395c69c5c77e411a863542ec8074</guid>
		<description><![CDATA[Asuragen, Inc. announced the launch of Signature® NPM1 Mutations (RUO), a multiplex reverse transcription PCR (RT-PCR) assay that enables the detection of NPM1 mutations. Asuragen's Signature® NPM1 Mutations is a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin (NPM1) gene. Asuragen is one of two exclusive licensees to NPM1.]]></description>
			<content:encoded><![CDATA[Asuragen, Inc. announced the launch of Signature® NPM1 Mutations (RUO), a multiplex reverse transcription PCR (RT-PCR) assay that enables the detection of NPM1 mutations. Asuragen's Signature® NPM1 Mutations is a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin (NPM1) gene. Asuragen is one of two exclusive licensees to NPM1.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/asuragen-inc-launches-signature%c2%ae-npm1-mutations-ruo-a-rapid-multiplex-assay-for-the-detection-of-npm1-mutations.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>New Hip Replacement Implant Designed To Cater To Women&#8217;s Needs - Orthopedic Surgeon At Rush Is A Developer Of Implant Device</title>
		<link>http://www.globalepolicy.org/new-hip-replacement-implant-designed-to-cater-to-womens-needs-orthopedic-surgeon-at-rush-is-a-developer-of-implant-device.htm</link>
		<comments>http://www.globalepolicy.org/new-hip-replacement-implant-designed-to-cater-to-womens-needs-orthopedic-surgeon-at-rush-is-a-developer-of-implant-device.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 09:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Bones / Orthopaedics]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://cc8b2453af91c38cc01c6c80531deea8</guid>
		<description><![CDATA[When it comes to hips and joints, one size does not fit all.  That's why women facing hip surgery are being offered a new option specifically designed with their anatomy in mind.  At Rush University Medical Center, orthopedic surgeons are offering a new "gender-specific" implant called the M/L Taper Hip Prosthesis with Kinectiv™ Technology.     Dr. Richard Berger, an orthopedic surgeon at Rush, helped design the new hip replacement made by Zimmer, Inc.]]></description>
			<content:encoded><![CDATA[When it comes to hips and joints, one size does not fit all.  That's why women facing hip surgery are being offered a new option specifically designed with their anatomy in mind.  At Rush University Medical Center, orthopedic surgeons are offering a new "gender-specific" implant called the M/L Taper Hip Prosthesis with Kinectiv™ Technology.     Dr. Richard Berger, an orthopedic surgeon at Rush, helped design the new hip replacement made by Zimmer, Inc.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/new-hip-replacement-implant-designed-to-cater-to-womens-needs-orthopedic-surgeon-at-rush-is-a-developer-of-implant-device.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>In Developing Nations, Improved Oxygen Systems Can Improve Child Pneumonia Mortality</title>
		<link>http://www.globalepolicy.org/in-developing-nations-improved-oxygen-systems-can-improve-child-pneumonia-mortality.htm</link>
		<comments>http://www.globalepolicy.org/in-developing-nations-improved-oxygen-systems-can-improve-child-pneumonia-mortality.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 07:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Respiratory / Asthma]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://b2d4ac295d6a15fb8cf5710a81c7c089</guid>
		<description><![CDATA[Child pneumonia mortality is decreased by the implementation of various  improved oxygen systems, including pulse oximeters and oxygen  concentrators, in the developing world. Additionally, this is cost  effective when compared to other interventions, according to an article  released on August 18, 2008 in The Lancet.     Acute respiratory infections, such as pneumonia, are a major health  issue for children in developing countries.]]></description>
			<content:encoded><![CDATA[Child pneumonia mortality is decreased by the implementation of various  improved oxygen systems, including pulse oximeters and oxygen  concentrators, in the developing world. Additionally, this is cost  effective when compared to other interventions, according to an article  released on August 18, 2008 in The Lancet.     Acute respiratory infections, such as pneumonia, are a major health  issue for children in developing countries.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/in-developing-nations-improved-oxygen-systems-can-improve-child-pneumonia-mortality.htm/feed</wfw:commentRss>
		</item>
		<item>
		<title>Successful Robot-Assisted Surgery For Urinary Abnormality</title>
		<link>http://www.globalepolicy.org/successful-robot-assisted-surgery-for-urinary-abnormality.htm</link>
		<comments>http://www.globalepolicy.org/successful-robot-assisted-surgery-for-urinary-abnormality.htm#comments</comments>
		<pubDate>Tue, 19 Aug 2008 07:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Urology / Nephrology]]></category>

		<guid isPermaLink="false">tag:www.medicalnewstoday.com://25c8af9086287a285322cf27d3999914</guid>
		<description><![CDATA[Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.    Their report appears online in the Journal of Urology and will be included in a future print issue.]]></description>
			<content:encoded><![CDATA[Ashok Hemal, M.D., a urologic surgeon from Wake Forest University Baptist Medical Center, and colleagues have reported success using robot-assisted laparoscopic surgery to repair abnormal openings between the bladder and vagina known as fistulas. Reporting on their experience with seven patients, Hemal and colleagues have the world's largest known success with the procedure.    Their report appears online in the Journal of Urology and will be included in a future print issue.]]></content:encoded>
			<wfw:commentRss>http://www.globalepolicy.org/successful-robot-assisted-surgery-for-urinary-abnormality.htm/feed</wfw:commentRss>
		</item>
	</channel>
</rss>
